Objectives The major clinical side effect of the ERBB2-targeted breast cancer therapy, trastuzumab, is a decline in the left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity.
Introduction
The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on the management of patients with HER2 + advanced and early breast cancer. The major adverse event for this drug is cardiotoxicity, but symptoms are not uniform across patients and differ from the well-known dose-dependent effect of anthracyclines [1] .
There are no clinically proven markers to predict which patients will experience cardiotoxicity following trastuzumab treatment. Left ventricular ejection fraction (LVEF) of less than 55%, age above 60 years, and antihypertensive medication before treatment are known risk factors [2] . The observed variability of cardiac symptoms in humans and animal models suggest a genetic influence. ErbB2-deficient conditional mutant adult mice develop a phenotype consistent with dilated cardiomyopathy (DCM) [3, 4] . Some forms of heart disease presenting with decreased LVEF in humans, such as familial dilated and hypertrophic cardiomyopathy, are known to have a strong heterogeneous genetic basis [5] . Onehundred ninety-seven published rare variants in more than 30 causative genes have been reported in the literature [6] . Common variants in these genes are overrepresented in sporadic cases [7] [8] [9] , suggesting the existence of modifying or risk variants that could be exacerbated by environmental stress factors such as trastuzumab and/or chemotherapy. To date, two common genetic polymorphisms within ERBB2, Ile655Val, and Pro1170Ala, have been associated with an increased risk of trastuzumab-related cardiotoxicity, but sample sizes Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
were small (N = 61-140 patients) [10] [11] [12] [13] [14] . Polymorphisms in several genes including ABCB1, CBR3 [15, 16] , RAC2, NCF4 [17, 18] , and SLC28A3 [19, 20] have been associated with anthracycline-related cardiotoxicity.
Trastuzumab-related cardiotoxicity commonly manifests as an asymptomatic decline in LVEF that is mostly reversible when treatment is stopped. However, it remains unclear whether trastuzumab therapy could have long-lasting effects on cardiac function such as progressive cardiac remodeling and DCM. This adverse effect of trastuzumab has resulted in strict eligibility criteria in clinical trials and/or discontinuation before completion of treatment; 5% of almost 3500 eligible patients in the NSABP-B31 and N9831 trials were not allowed to initiate trastuzumab therapy and a further 5% of initially eligible women discontinued treatment because of cardiac side effects [21, 22] . Data from multiple-randomized adjuvant trials and observational studies suggest that the rate of discontinuation of trastuzumab treatment ranges between 6 and 31%, mainly because of cardiotoxicity. In patients aged older than or equal to 65 years, this figure increases to a notable and clinically relevant rate of 41% [23] . Identification of genetic variants that predict which patients are predisposed to cardiotoxicity could improve patient treatment and management.
Observations of trastuzumab-related cardiotoxicity are further complicated by the use of anthracyclines before trastuzumab treatment, particularly as anthracyclines can result in late-onset cardiac dysfunction [24] . All patients in the N9831 study received anthracyclines and paclitaxel before trastuzumab. The patients who had LVEF dysfunction at 6 years follow-up were the same patients who had LVEF dysfunction during trastuzumab-paclitaxel therapy [25] . In addition, LVEF dysfunction at 6 years was not statistically different among the chemotherapy only and chemotherapy plus trastuzumab treatment arms, therefore long-term LVEF dysfunction may not be related to trastuzumab but, possibly, to exposure to anthracyclines and/or increasing age. This is an important point because identification of genetic variants that predict which patients are predisposed to anthracycline cardiotoxicity could allow these patients to use a different chemotherapy regimen, allowing them to be eligible for and to complete the trastuzumab therapy. The large size, design, and detailed cardiac data collected in N9831 allowed us to examine the genetic influence of trastuzumab on cardiotoxicity in the context of both anthracycline chemotherapy and combination chemotherapy and trastuzumab.
Methods
Detailed information about the methods and study population are available in the Supplementary material (Supplemental digital content 1, http://links.lww.com/FPC/ B255). Briefly, genome-wide genotyping was performed by Affymetrix Axiom array from which 618 793 SNPs passed genotyping quality control. Primary analysis consisted of patients from N9831, arms BC (N = 800 individuals), who received doxorubicin, paclitaxel, and trastuzumab ( Fig. 1) . We performed statistical analyses using R, version 3.1.1, PLINK, version 1.07, and Locus Zoom [26] . Linear regression was used for change in LVEF (lowest recorded LVEF − baseline LVEF), adjusting for age, baseline LVEF, antihypertensive medications, and the first two principle components in the 800 patients in arms BC who received combination chemotherapy and trastuzumab.
We report novel associations at P < 1 × 10 − 5 in these patients. We also report on published associations of trastuzumab-related cardiotoxicity in the variants ERBB2 Ile655Val and Pro1170Ala [10, [12] [13] [14] from patients in arms BC and on published associations of anthracycline-related cardiotoxicity at the ABCB1, CBR3, RAC2, NCF4, SLC28A3, RARG, and UGT1A6 loci [27] in patients from arms A, B, and C combined, who all received doxorubicin and paclitaxel.
Results
Suggestive loci associated with combination chemotherapy and trastuzumab-induced decline in LVEF Seeking modifying/ susceptibility genes for cardiotoxicity in patients undergoing treatment for HER2-positive breast cancer, we used a genome-wide association approach. Our primary analysis consisted of DNA samples from 800 patients (arms BC) who received doxorubicin, paclitaxel, and trastuzumab and were determined to be of White/non-Hispanic origin with complete LVEF data from baseline (before doxorubicin) and up to 2 years after treatment.
This analysis yielded six regions at P < 1 × 10
, with associated variants within or close to LDB2, BRINP1, an intergenic region on chromosome 6, RAB22A, TRPC6, and LINC01060 (Table 1 ) (QQ and Manhattan plots; Supplementary Fig. 2 , Supplemental digital content 1, http://links.lww.com/FPC/B255). Locus Zoom plots of each region are shown in Supplementary Fig. 3 (Supplemental digital content 1, http://links.lww.com/FPC/B255). The most significant variant, rs55756123, P = 8.93 × 10 − 8 mapped within 500 bp of the 3′-UTR of LDB2. Imputation did not identify any additional variants at this level of significance or any additional coding variants at P < 0.05. In the subset of patients with congestive heart failure (CHF) (N = 10) versus those without (N = 789), a Fisher's exact test of rs55756123 genotype counts was significant, P = 0.007, suggesting enrichment of the associated allele in individuals with the worst cardiac outcome.
We observed a total of 18 SNPs, P < 1 × 10 − 5 at the BRINP1 locus; the most significant intronic variant, rs62568637, P = 6.01 × 10 − 7 and variants in the 3′-flanking region, rs10117876 and rs7038023, P = 5.86 × 10 Table 4 , Supplemental digital content 1, http://links.lww.com/FPC/B255). Imputation at this region identified a more significant 3′-flanking variant, rs7037449, P = 1.87 × 10 − 7 in high LD with the other 3′-flanking variants. rs4305714, P = 1.39 × 10 − 6 maps to an intergenic region on chromosome 6p22.3. Imputation across the region was supportive, yielding an additional 18 variants at P < 1 × 10 − 5 and two additional variants in high LD, rs72836853 and rs10485148 at P = 9.85 × 10 . The positive GERP score for this variant (2.47) may suggest some level of sequence conservation at this locus. Imputation across this region yielded two additional SNPs at the same level of significance in very high LD, rs1045408 and rs6128327, P = 3.48 and 3.38 × 10 − 6 , respectively, both of which map to sequences with very high GERP scores (range: 4.32-5.40).
An intronic variant, rs77679196, within TRPC6 was associated at P = 7.72 × 10
. Imputation across the region yielded one additional SNP in the 5′-flanking region, with a slightly stronger association, rs75865789, β = − 8.62 (95% confidence interval: − 12.07 to − 5.178), P = 1.14 × 10
. In the subset of patients with CHF (N = 10) versus those without (N = 789), a Fisher's exact test of rs77679196 genotype counts was significant (P = 0.019), suggesting enrichment of the associated allele in individuals with the worst cardiac outcome.
Associated variants in the final significant region were entirely intergenic, the closest gene being LINC01060. Imputation supported the most significant SNP, rs7698718, with an additional variant at P < 1 × 10 − 5 all in high LD, but no variants of greater association were identified.
We reasoned that variants associated with cardiotoxicity specifically from doxorubicin would be significant or show a trend in the chemotherapy arm only and report these data separately in Table 1 . None of the six regions from our discovery analyses of patients who received chemotherapy in combination with trastuzumab (N = 800) were significant at P < 0.05 (one tailed) in the patients who received chemotherapy only (N = 391). LDB2 and RAB22A showed an effect in the opposite direction in patients who received chemotherapy only, and combined analyses of all patients (N = 1191) became less significant, P = 1.81 × 10 − 6 and 0.0015, respectively. The most significant SNPs at BRINP1 and the intergenic region close to LINC01060 showed effects in the same direction and became slightly more significant in combined analyses of all patients (N = 1191), BRINP1, rs62568637, P = 4.73 × 10 − 6 ; LINC01060, P = 1.63 × 10 − 6 . The intergenic SNP, rs4305714 became less significant in the combined analysis of all patients, P = 1.20 × 10 − 5 . rs7769196 in intron 1 of TRPC6 did show a similar effect size in the same direction and a trend for association (P = 0.06, one tailed) in patients who received chemotherapy only, increasing significance in combined analysis of all patients, P = 1.63 × 10 − 6 .
Replication of variants associated with ERBB2-induced cardiotoxicity
Our study failed to find association of decline in LVEF with either of the published associated ERBB2 variants, rs1136201 (I655V) and rs1058808 (P1170A) [10] [11] [12] [13] [14] . To be consistent with published associations of the I655V variant, we also performed genotypic analyses of the AG + GG genotypes versus the AA genotype on a case control basis, where cases were defined as a decrease of at least 10% points from baseline with a resulting LVEF of less than 50%, a decrease of 15% with respect to baseline, or any decrease resulting in LVEF less than 45% at least once during the treatment or clinical manifestation of CHF [14] . We did not observe any association of the I655V or P1170A variants with either linear or logistic models ( Table 2) . ; trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly (qw). LVEF, left ventricular ejection fraction. Table 1 Linear regression analysis of maximum decline in left ventricular ejection fraction Genotype count for each SNP is shown in the subset of patients with CHF separated for arms BC and arm A, with genotype counts of allele 1 homozygote/heterozygote/allele 2 homozygote and minor allele frequency in parentheses.
CHF, congestive heart failure; L95 and U95, lower and upper 95% confidence intervals; LVEF, left ventricular ejection fraction; MAF, minor allele frequency; P, P value is shown for arms BC and arm A additive linear regression analysis; SNP, single nucleotide polymorphism.
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We also assessed association at ERBB2 by imputation including 200 kb flanking region and linear regression of decline in LVEF, plotted in Locus Zoom ( Supplementary  Fig. 4 , Supplemental digital content 1, http://links.lww.com/ FPC/B255) in those patients who received combination chemotherapy and trastuzumab (arms BC). This analysis identified 95/943 SNPs at P < 0.05, although none of these remained significant following correction for multiple testings.
Variants associated with anthracycline-induced cardiotoxicity
Several SNPs have been associated with anthracyclineinduced cardiotoxicity [16, 19, 20, 27, 28] . Under our linear model of decline in LVEF, we observed a significant association of the CBR3 V244M variant in combined analyses of all patients (N = 1191), P = 0.004, β = 0.84 when A (Met) allele is taken as a reference [15, 16] . We also observed association with the published ABCB1 variant rs2235047 (P = 0.018) and a trend for association of rs17863783 variant in UGT1A6 (P = 0.078). We also looked for enrichment of the associated allele in the subset of individuals with CHF (N = 17). There was no evidence of enrichment at either the CBR3 or ABCB1 locus. However, we did observe enrichment of reported associated alleles at the NCF4 and RARG loci in patients with CHF. Allele A of the NCF4 5′-flanking SNP, rs1883112, presented with a frequency of 0.44 in all patients who received chemotherapy (N = 1191), but only 0.24 (8/34 alleles) in patients with CHF, odds ratio (OR): 0.35, P = 0.011. The leucine allele of rs2229774 at the RARG locus was enriched in CHF patients relative to all patients who received chemotherapy (0.15 vs. 0.07) and showed a trend for association, P = 0.076. Locus Zoom plots are shown in Supplementary Fig. 5 (Supplemental digital content 1, http://links.lww.com/FPC/B255).
Discussion
Cardiotoxicity is a major clinical side effect of both anthracycline and trastuzumab therapies, with a higher incidence in patients receiving combination treatment compared with those receiving only anthracycline [25, 29] . The extent and frequency of cardiotoxicity are not uniform across patients, leading us to hypothesize a genetic influence. We performed a genome-wide association of decline in LVEF in patients treated with trastuzumab from the N9831 trial. This trial led to the use of trastuzumab as a standard of care in early onset HER2 + breast cancer. Our first approach used a quantitative analysis of the maximum observed decline in LVEF and DNA variants in patients from arms BC (N = 800) who received doxorubicin, paclitaxel, and trastuzumab. We corrected for multiple testing with Benjamini-Hochberg and report those variants at q < 0.2 for a total of 23 variants (P < 1 × 10 − 5 ), from six novel loci: limb domain binding 2 (LDB2), an adapter molecule of transcriptional regulatory complexes [30, 31] ; BMP/retinoic acidinducible neural-specific protein 1 (BRINP1), a suppressor of cell cycle progression [32] ; transient receptor potential cation channel, subfamily C, member 6 (TRPC6), a central mediator of hypertrophic cardiomyopathy, cardiac remodeling [33] [34] [35] [36] ; a member of the RAS oncogene family (RAB22A) involved in endocytic trafficking [37] [38] [39] ; a LINC RNA, LINC10160; and an intergenic region on chromosome 6.
Patients in arms BC received both doxorubicin and trastuzumab. Therefore, in an effort to discriminate between doxorubicin and trastuzumab-mediated cardiotoxicities, we reasoned that loci associated with decline in LVEF induced specifically by doxorubicin would be replicated in arm A alone. However, none of the top variants were significant, P < 0.05, in the patients in arm A (N = 391) ( Table 1) . We did observe a trend for association of decline in LVEF for the intronic variant in TRPC6 in patients who received chemotherapy only. This association was in the same direction and similar effect size as observed in patients receiving chemotherapy and trastuzumab, P = 0.06 (one tailed), suggesting that the TRPC6 variant could be a result of chemotherapy. Evidence from the literature could support this hypothesis, because TRPC6 expression that is increased in cardiac tissue from patients with DCM [35] is also Association analyses were performed assuming an additive effect in both linear and logistic regression models. For logistic regression, we report genotype counts, odds ratio and P values using the more stringent definition of cases as per Gomez Pena et al. [14] . Decrease of at least 10% points from baseline with a resulting LVEF of less than 50% or decrease of 15% with respect to baseline, or any decrease resulting in LVEF less than 45% at least once during the treatment or clinical manifestation of CHF. CHF, congestive heart failure; L95 and U95, lower and upper 95% confidence intervals; LVEF, left ventricular ejection fraction; OR, odds ratio; SNP, single nucleotide polymorphism.
up-regulated by doxorubicin [40] . The failure to replicate other variants in patients in arm A could infer that the novel associations in arms BC are induced by combination chemotherapy and trastuzumab, although we acknowledge that arm A (N = 391) is smaller than arms BC (N = 800) and may lack statistical power to replicate. We do not believe associations in Table 1 are a statistical artifact of different cumulative doses of doxorubicin as all patients in this analysis received the same dose (4 × 60 mg/m 2 ) regimen completing chemotherapy with postanthracycline LVEF remaining above 50% to continue with trastuzumab treatment.
To further discriminate between chemotherapy and trastuzumab-mediated cardiotoxicity, we also performed an exploratory analysis of each novel region. We hypothesized that true risk alleles of cardiotoxicity might be enriched in the subset of patients with CHF. At LDB2, BRINP1, and TRPC6 (low frequency variants, MAF < 0.02), we observed at least five-fold enrichment in the subset of patients with CHF who received trastuzumab (N = 10). Interestingly, in those patients with CHF who received chemotherapy only (N = 7) we did not observe any of the putative risk alleles at these loci, suggesting that these associations may be trastuzumab-mediated with the caveat that our subset of patients with CHF is underpowered. In contrast, for the most common associated variants in Table 1 , chr6 intergenic region, RAB22A and LINC01060, we observed enrichment in those patients with CHF who received chemotherapy only (MAF: 0.50, 0.57, and 0.36, respectively). We did not observe the same trend in the patients receiving trastuzumab who also developed CHF. If these variants are truly associated with doxorubicin and/or trastuzumab-mediated cardiotoxicity, one could hypothesize the existence of large effect size, low frequency variants that increase susceptibility to cardiotoxicity with combination chemotherapy and trastuzumab, and the existence of common cardiac risk variants that increase susceptibility to anthracycline-related cardiotoxicity.
Our GWAS data also included variants from the current literature that were reported to be associated with cardiotoxicity from either, trastuzumab, anthracycline, or combination therapy. We failed to observe genome-wide significant association with any variant at ERBB2, the target of trastuzumab. We did not observe any association at P < 0.05 for SNPs reported to be associated with trastuzumab-related cardiotoxicity in the current literature (i.e. rs1136201, I655V and rs1058808, P1170A). There are several possible reasons for this failure to replicate previous findings. We ruled out genotyping error on the basis of concordant genotypes from multiple probes at rs1136201, genotypic data in Hardy-Weinberg equilibrium, observed allele frequencies in line with other reported studies and adequate cluster plots ( Supplementary Fig. 7 , Supplemental digital content 1, http://links.lww.com/FPC/B255).
We next considered our definition of cardiotoxicity as a reason for lack of replication with ERBB2 I655V and P1170A. Our primary analysis used a quantitative model of maximum decline in LVEF. Published associations used a binary definition of cardiotoxicity or no cardiotoxicity, but with different definitions in each case, including decrease in LVEF of at least 20% points [10] ; decrease in LVEF of at least 10% points to less than 50% or any decrease to less than 45% [11] ; decrease of more than 10% points to less than 50% or any decrease of more than 15% or any decrease resulting in less than 45% or diagnosis of CHF [14] . Hence, we also looked for association with the same binary definition as Gomez Pena et al. [14] . Again, we did not observe any associations, P < 0.05. Acknowledging the caveat of the arbitrary definition of cardiotoxicity and the models we used, it is possible that our lack of replication was simply because of a smaller sample size in previous studies. Our data set from N9831 patients treated with trastuzumab (N = 800) was over two-fold greater compared with the four published studies combined (N = 344, range: 61-132 patients [14] ), which showed large ORs ranging from 3.80 to 5.80. We noted that there were no published negative studies of these variants with cardiotoxicity, which may suggest a publication bias toward positive associations when using small sample sizes.
Our analysis of published SNPs associated with anthracycline cardiotoxicity in all patients who received doxorubicin (arms A, B, and C combined, N = 1191) was more successful in that we did observe association of the CBR3 V244M variant in our quantitative analysis of maximum decline in LVEF (P = 0.004) with supporting evidence from multiple SNPs at this locus. Carbonyl reductases (CBRs) catalyze reduction of anthracyclines to cardiotoxic alcohol metabolites and polymorphisms in CBR1 and CBR3 influence the synthesis of these metabolites. CBR3 V244M was previously associated with a dose-dependent risk of anthracycline-related cardiomyopathy in childhood cancer survivors [15] , and with cardiotoxicity in a cohort of breast cancer patients [16] . In a literature review entitled 'Recommendations for genetic testing to reduce the incidence of anthracyclineinduced cardiotoxicity', it was deemed that CBR3 required further validation. Our study confirms association of this variant in patients with breast cancer.
Similarly, we observed association of a variant in ABCB1, rs2235047, also previously associated with anthracyclineinduced cardiotoxicity in children, where 266 were controls (defined as systolic function > 30% during and after therapy, with follow-up of > 5 years after completion of anthracycline therapy) and 78 cases (defined as systolic function ≤ 26% at any time during or after anthracycline therapy) [19] . This variant was not confirmed in a further study of children, consisting of 46 cases and 131 controls, analyzed with the same methodology from the same group [20] , perhaps because of lack of power. However, in this N9831 Cardiotoxicity GWAS Serie et al. 383 study we observed an association of similar magnitiude (β = − 2.34, P = 0.018) in our linear model of decline in LVEF in 1191 patients receiving doxorubicin, adding further evidence for this association. Certainly, this gene is a reasonable candidate because of its involvement in drug excretion in the kidney, liver, and heart [41, 42] . Specifically, changes in ABCB1 expression or function prolong the presence of both doxorubicin in cardiac tissue and its cardiotoxic metabolite, doxorubicinol, within cardiac tissue [43] . Furthermore, the ERBB2 inhibitor, lapatinib, has been shown to inhibit the function of ABCB1 [44] , suggesting a possible mechanism for increased cardiotoxicity as a result of doxorubicin in combination with HER2-targeted therapy.
We did not observe an association of published SNPs associated with doxorubicin-induced cardiotoxicity in SLC28A3, NCF4, RAC2, RARG, and UGT1A6 in our linear model of decline in LVEF in 1191 patients receiving doxorubicin (Table 3) . Given these were associations with CHF rather than decline in LVEF, we also tested for these variants in the limited subset of patients (N = 17) with CHF. Aminkeng et al. [28] reported a highly signficant association of the 427Leu variant within retinoic acid receptor-γ, RARG (rs2229774, Ser427Leu) with CHF in three studies of children (cases N = 32, 22, and 19, respectively) treated with anthracyclines (either doxorubicin, daunorubicin, idarubicin, epirubicin, or mitoxantrone). In our smaller subset of CHF patients from the N9831 trial treated with doxorubicin, we observed a weak association of the 427Leu variant, OR = 2.39, P = 0.038 (one tailed). We also observed association of the NCF4 rs1883112 A allele, OR 0.35, P = 0.01 (two tailed) (A allele frequency in CHF patients = 0.24 versus 0.44 in patients who were not confirmed with CHF). However, our finding is in the opposite direction to other reported associations. The AA genotype of this variant was previously associated with CHF in adult non-Hodgkin lymphoma patients treated with doxorubicin, OR: 2.00, P = 0.018 [18] and the A allele was associated with CHF in cancer patients treated with anthracyclines, OR: 5.11, P = 0.016 [45] .
A limitation of our study is the inability to validate our finidngs using other methods. Recognizing this limitation, we scanned the literature for reported cardiac modifying genes in animal models. This led us to examine four genes (SORBS2, RXRA, DNAJB6, and ANO5) reported as cardiac modifiers of doxorubicin-induced cardiotoxicity in zebrafish and/or mouse models [46, 47] . Suggesting that our data can be replicated, we also identified variants in our study of N9831: P < 0.001 in SORBS2 and RXRA and P < 0.01 in DNAJB6 (Supplementary Table 3 , Supplemental digital content 1, http://links.lww.com/FPC/B255). These findings suggest that these genes require further study as genes modified by chemotherapy treatments that could increase the risk for cardiomyopathy in patients.
Conclusion
Our study confirmed previously reported associations of chemotherapy-induced cardiotoxicity with variants in the ABCB1 and CBR3 genes. We failed to replicate previous findings at ERBB2 with any model of cardiotoxicity (linear or logistic); however, our sample size was significantly larger than other published studies suggesting that previous associations may have occurred because of small sample size. In an effort to identify novel loci relevant to patients receiving combination chemotherapy and trastuzumab, we identified six potential susceptibility loci. Further study is needed to confirm the role of these loci in trastuzumabinduced cardiomyopathy. Additive effect linear regression analyses in all arms combined. Logistic regression was performed in those cases (N =17) with congestive heart failure versus all other patients. CHF, congestive heart failure; L95 and U95, lower and upper 95% confidence intervals; LVEF, left ventricular ejection fraction; NA, not available; OR, odds ratio. P values <0.05 are highlighted in bold.
